EUCTR2015-002602-36-DE进行中(未招募)1 期
Efficacy and safety of high dose glucocorticosteroid treatment for idiopathic sudden sensorineural hearing loss (HODOKORT) - HODOKORT
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 312
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-female and male adults (18-80 years)
- •-unilateral sensorineural hearing loss
- •-sudden onset of hearing loss (occurring within 24 hours)
- •-unknown etiology (no other ear or CNS disease)
- •-change in hearing threshold due to ISSHL of 30 dB or higher (as compared to a pre-event audiogram, the audiogram of the unaffected ear, or the ISO) for the 3 most affected contiguous frequencies in the affected ear but not less then 50 dB absolute threshold as average of the 3 most affected contiguous frequencies between 0,25 und 8 kHz < 50 dB HL
- •-enrolment and treatment within 7 days from onset
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 156
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 156
排除标准
- •-recurrent ISSHL at the affected side (< 12 months)
- •-known other otologic cause of ISSHL (e.g.: middle ear disease; vestibular schwannoma; known fluctuating hearing loss; Meniere’s disease)
- •-absolute hearing threshold as average of the 3 most affected contiguous frequencies between 0,25 und 8 kHz < 50 dB HL
- •-certain systemic diseases (treatment for or chronically active infection such as HIV, hepatitis C or B, tuberculosis, hard to balance diabetes mellitus, ongoing immunosuppressive treatment for rheumatic or chronic inflammatory disease, unstable atherosclerotic disease, heart failure >NYHA II, suicidality, severe osteoporosis, active peptic ulcer, uncontrolled (syst. >180 mmHg or diast. >100 mmHg) arterial hypertension)
- •-treated mental disorders or after surgical interventions in the last 6 weeks: inclusion only after critical evaluation by the investigator
- •-pre-treatment of ISSHL with glucocorticosteroids or hyperbaric oxygen
- •-conductive deafness (air-bone gap 4PTA0,5-4kHz >10 dB)
- •-pregnancy or lactation
研究者
相似试验
进行中(未招募)
2 期
Efficacy and safety of high dose glucocorticosteroid treatment foridiopathic sudden sensorineural hearing lossH91Other hearing lossDRKS00010738Martin-Luther-Universität Halle-Wittenberg325
招募中
3 期
Efficacy of steroid treatment on heart blocks secondary to heart valve surgeryAdvanced atrioventricular block following heart valve surgery.Atrioventricular and left bundle-branch blockIRCT20180430039488N1Tehran Heart Center150
已完成
不适用
Efficacy and safety of Hydrocortison-POS N1% and 2.5% versus Ficortril 0.5% in the treatment of acute inflammation of the ocular surface or adnexa for which steroid treatment is indicatedISRCTN15464650RSAPHARM Arzneimittel GmbH (Germany)411
招募中
3 期
Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19IRCT20080901001165N52Bagheiat-allah University of Medical Sciences50
招募中
不适用
Efficacy and Safety of corticosteroids and vigabatrin plus corticosteroids in infantile spasmInfantile spasm.Epileptic spasms, not intractable, without status epilepticusG40.822IRCT20200414047072N2The Children's Hospital & the Institute of Child Health, Multan.320
